Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Operating Leases (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Operating Leases for 4 consecutive years, with $949000.0 as the latest value for Q3 2025.

  • Quarterly Operating Leases changed N/A to $949000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $949000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $37000.0 for FY2023, 85.26% down from the prior year.
  • Operating Leases hit $949000.0 in Q3 2025 for ARS Pharmaceuticals, down from $1.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.1 million in Q3 2021 to a low of $37000.0 in Q4 2023.
  • Historically, Operating Leases has averaged $1.7 million across 4 years, with a median of $949000.0 in 2025.
  • Biggest five-year swings in Operating Leases: surged 128.63% in 2022 and later tumbled 96.41% in 2023.
  • Year by year, Operating Leases stood at $480000.0 in 2021, then tumbled by 47.71% to $251000.0 in 2022, then plummeted by 85.26% to $37000.0 in 2023, then soared by 2464.86% to $949000.0 in 2025.
  • Business Quant data shows Operating Leases for SPRY at $949000.0 in Q3 2025, $1.1 million in Q2 2025, and $37000.0 in Q4 2023.